Anavex Life Sciences (NASDAQ:AVXL – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $40.00 target price on the biotechnology company’s stock.
Separately, EF Hutton Acquisition Co. I raised shares of Anavex Life Sciences to a “strong-buy” rating in a research report on Monday, July 22nd.
Check Out Our Latest Stock Analysis on AVXL
Anavex Life Sciences Price Performance
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter last year, the company posted ($0.14) EPS. As a group, research analysts expect that Anavex Life Sciences will post -0.55 EPS for the current year.
Hedge Funds Weigh In On Anavex Life Sciences
A number of hedge funds have recently made changes to their positions in AVXL. SG Americas Securities LLC purchased a new position in shares of Anavex Life Sciences during the 2nd quarter worth approximately $57,000. Fiduciary Alliance LLC purchased a new position in Anavex Life Sciences in the 1st quarter valued at approximately $67,000. EntryPoint Capital LLC boosted its position in Anavex Life Sciences by 371.1% in the 1st quarter. EntryPoint Capital LLC now owns 20,007 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 15,760 shares during the period. The Manufacturers Life Insurance Company boosted its position in Anavex Life Sciences by 8.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 2,401 shares during the period. Finally, Saxon Interests Inc. purchased a new position in Anavex Life Sciences in the 1st quarter valued at approximately $136,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Further Reading
- Five stocks we like better than Anavex Life Sciences
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
- Trading Stocks: RSI and Why it’s Useful
- AI Boom Fuels Demand for Dominion Energy Stock
- What does consumer price index measure?
- Cathie Wood Cuts Robinhood Holdings—Follow Her Lead or Stay Put?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.